Ascendis Pharma AS
Latest From Ascendis Pharma AS
Pfizer adds to its rare disease portfolio with purchase of Therachon, a Swiss company working in achondroplasia. But whether it can catch up with Biomarin’s Phase III vosoritide is still to be seen.
Finance Watch: Panic Over FDA Commissioner's Resignation Was Short-Lived, Though IPOs Still Languish
Public Company Edition: Biotech stocks sank when US FDA Commissioner Scott Gottlieb announced his departure, but have nearly recovered to pre-resignation levels, except for newly public firms. Also, Biohaven's raises cash for PRV purchase and Endo issues $1.5bn in new debt.
Asia Deal Watch: MEI Partners ME-401 With Japan’s Kyowa Hakko Kirin, Following Chinese Deal With BeiGene
About a month after signing a development and commercialization partnership in China for its PI3K delta inhibitor, MEI signs a deal for Japanese rights to the compound with Kyowa Hakko Kirin. Cue and LG Chem partner to develop targeted T-cell therapies for cancer.
Emerging Company Profile: With backing from BridgeBio, San Francisco start-up QED sees potential for drug licensed from Novartis in a number of tumor types, following the recent presentation of promising results in Phase II for bile duct cancer and Phase I for advanced urothelial cancer.
- Large Molecule
- Controlled Release
- Drug Delivery
- Therapeutic Areas
- Metabolic Disorders
- Western Europe
- Parent & Subsidiaries
- Ascendis Pharma AS
- Senior Management
Jan Møller Mikkelsen, Pres. & CEO
Scott T Smith, SVP, CFO
Harald Rau, SVP, CSO
Jonathan Leff, MD, SVP, CMO
Thomas A Larson, Chief Commercial Officer
- Contact Info
Ascendis Pharma AS
Phone: (45) 70 22 22 44
Tuborg Blvd. 12
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.